Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Among Asian countries, South Korea was the first to approve liraglutide as a treatment for obesity. Thus, the clinical effectiveness of liraglutide has not been studied in Asian populations. In this study, we retrospectively analyzed obese patients [body mass index (BMI) >27 kg/m 2] who were treated with liraglutide between March 2018 and March 2019 in a single clinic. Weight, BMI, HbA1c, and clinical data were collected before liraglutide treatment. Changes in body weight and composition and their relationships with clinical variables were examined at re-prescription dates within 30, 60, 90, and 180 days. A total of 169 subjects were studied. The average age was 41.5 years, and 42% of the subjects were male. The average weight was 85.2 kg, and the average BMI was 30.8 kg/m 2. Weight reduction was significant (–5.5 ± 3.4 kg, 30 days: –3.2 ± 1.8 kg, 60 days: –4.5 ± 2.3 kg, 90 days: –6.3 ± 2.6 kg, 180 days: –7.8 ± 3.5 kg) during the follow-up period and increased with longer treatment time (P < .001). The percentages of subjects that showed ≥ 5% and ≥ 10% body weight reduction were 62.1% and 17.2%, respectively. In the body composition analysis, skeletal muscle weight loss was –3.56 ± 29.7%, which was significantly smaller than fat weight loss of –11.06 ± 10.4% (P = .03). Weight loss was not significantly related to age, sex, baseline BMI, baseline HbA1c, smoking status, alcohol consumption, coffee intake. In conclusion, Liraglutide treatment led to meaningful weight loss in South Korean patients, and fat mass reduction was prominent during treatment. Furthermore, liraglutide showed greater clinical effectiveness with longer treatment time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, patients with type 2 diabetes were also represented in many studies51,53,54,56,57,59,62,63,65,68–71.”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“As in RCT, participants were mostly adults (mean age 30.4–55.5 years) and females (60–95%) with class II obesity, except for studies conducted in China and South Korea, enrolling patients with a mean BMI ranging from 30.8 to 33 kg/m2 53,54,62,66.”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [62]
In the citing paper
“Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are effective antiobesity drugs.”
From GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15268-3 · Cited by 12,717
Abarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Diabetes in Asia: Epidemiology, Risk Factors, and Pathophysiology
Chan, J. C. N., Malik, V., Jia, W., Kadowaki, T., Yajnik, C. S., Yoon, K.-H., & Hu, F. B. (2009) · JAMA · doi:10.1001/jama.2009.726 · Cited by 1,997
Long-term weight loss maintenance
Wing, R. R., & Phelan, S. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/82.1.222s · Cited by 1,941 · cited 1×
“However, the overall effects of behavioral therapies in weight loss maintenance can be meaningful yet small, and can result in a gradual regain of the weight.([4,5]) Pharmacological treatments can act as an adjunct to behavioral treatments, especially for cases in which lifestyle changes fail to produce the desired we…”
BackgroundMechanisms, Pathophysiology, and Management of Obesity
Heymsfield, S. B., & Wadden, T. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1514009 · Cited by 1,867
New trends on obesity and NAFLD in Asia
Fan, J.-G., Kim, S.-U., & Wong, V. W.-S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.06.003 · Cited by 1,083
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Dombrowski, S. U., Knittle, K., Avenell, A., Araujo-Soares, V., & Sniehotta, F. F. (2014) · BMJ · doi:10.1136/bmj.g2646 · Cited by 816
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 1×
“Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analog that has 97% similarity to human GLP-1 and is known to lower body weight by reducing appetite and calorie intake.([8,9]) Randomized controlled studies have proven that liraglutide prescribed up to 3.”
Background
Cited by
GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans
Kim, K. S., Park, J. S., Hwang, E., Park, M. J., Shin, H. Y., Lee, Y. H., Kim, K. M., Gautron, L., Godschall, E., Portillo, B., et al. (2024) · Science · doi:10.1126/science.adj2537 · Cited by 148
Self-citationEffectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
Park, J. S., Kim, K. S., & Choi, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0106 · Cited by 58
Self-citationIncretin-based therapies for the treatment of obesity-related diseases
Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00030-5 · Cited by 48
Anyiam, O., Ardavani, A., Rashid, R. S. A., Panesar, A., & IDRIS, I. R. (2025) · Obesity Reviews · doi:10.1111/obr.13916 · Cited by 48
Metadata
- Authors
- Park, J. S., Kwon, J., Choi, H. J., & Lee, C.
- Affiliations
- Seoul National University (KR)
- Seoul Happiness Clinic of Internal Medicine, Republic of Korea.
- Corresponding author
- Lee, Changhyun
- Venue
- Medicine
- Published
- 2021-01-15
- Volume
- 100
- Issue
- 2
- Pages
- e23780
- ISSN
- 0025-7974 (ISSN-L)
- 1536-5964
- PMC
- PMC7808520
- OpenAlex
- W3120644852
- Cited by
- 27
- References
- 27
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 7 · 2023: 9 · 2022: 4
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Medicine (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- National Research Foundation of Korea (NRF) Grant funded by the Korean Government [MIST] (NRF-2018R1A5A2025964)
- Creative-Pioneering Researchers Program through Seoul National University (SNU) The Seoul National University Hospital Medical Research Collaborating Center (none)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- liraglutide, obesity, weight loss, GLP-1 receptor agonists, body composition, fat mass reduction, skeletal muscle, South Korean patients, Asian populations, treatment duration
- MeSH terms
- Liraglutide, Adult, Blood Glucose, Body Weights and Measures, Dose-Response Relationship, Drug, Female, Glycated Hemoglobin, Humans, Life Style, Male, Middle Aged, Obesity, Retrospective Studies, Weight Loss, Body Mass Index, Glucagon-Like Peptide 1, Republic of Korea
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia. https://app.cochat.ai/papers/10.1097/md.0000000000023780
- The paper
- Park, J. S., Kwon, J., Choi, H. J., & Lee, C. (2021). Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia. Medicine. https://doi.org/10.1097/md.0000000000023780
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.